Case Study of the WeekIs this a low-grade confined dysplasia or a more aggressive dysplasia-associated lesion or mass (DALM)?
Read More
RedPath in the NewsMolecular Diagnostics Company, RedPath, Appoints Dennis M. Smith, Jr., M.D. as Chief Executive Officer
Read
RedPath Receives Two Technology Grants for Development of PathFinderTG® Platform
Read
EventsRedPath's Mission is to facilitate superior disease diagnosis.
RedPath's Vision is to be recognized by clinicians, pathologists, patients and reimbursement organizations as the source for objective diagnosis and characterization of cancer, leading to optimal treatment and improved patient outcomes.